RATIONALE: Human immunodeficiency virus (HIV) infection is a risk factor for pulmonary hypertension (PH). Chronic hepatitis C virus (HCV) infection may have unique or synergistic effects on the pulmonary vasculature, but the prevalence and risk factors for PH in HIV-HCV coinfected persons are not known. OBJECTIVES: To define the prevalence of echocardiographic PH in a cohort of patients with HIV-HCV coinfection, to compare this estimate with the reported prevalence of PH among those with HIV infection alone, and to identify potential risk factors for PH in coinfected individuals. METHODS: We performed a retrospective study of HIV-HCV coinfected patients followed at our institution from 2003 to 2012 with evidence of HCV infection (positive HCV antibody, measurable HCV ribonucleic acid viral load, and/or genotype) within 6 months of transthoracic echocardiogram. PH was defined by an estimated pulmonary artery systolic pressure (PASP) of greater than or equal to 40 mm Hg or more than moderate right ventricular dysfunction. We excluded those diagnosed with cirrhosis, left ventricular ejection fraction less than 50%, or more than moderate aortic or mitral valve disease. MEASUREMENTS AND MAIN RESULTS: Sixty-eight patients were included, and 43 had adequate estimates of PASP. The median (interquartile range) age was 52 (48-57) years, and 45 (67%) were men. Eight (19%) had PH, and three (7%) had more than moderate right ventricular dysfunction. After age and sex adjustment, interferon (IFN)-based HCV treatment was associated with higher PASP (β, 6.00 mm Hg; 95% confidence interval, 0.09-11.90; P = 0.047) and with the risk of PH (odds ratio, 5.65; 95% confidence interval, 1.07-29.93; P = 0.042). These associations persisted after adjustment for comorbidities but were attenuated by adjustment for duration of HCV diagnosis. CONCLUSIONS: The prevalence of echocardiographic PH may be higher in HIV-HCV coinfected individuals than in those with HIV monoinfection. IFN-based HCV treatment and time since HCV diagnosis were associated with the development of PH as assessed by echocardiography. Further studies are needed to examine HIV-HCV coinfection, HCV treatment, and duration of infection as possible causes of pulmonary vascular disease.
RATIONALE: Human immunodeficiency virus (HIV) infection is a risk factor for pulmonary hypertension (PH). Chronic hepatitis C virus (HCV) infection may have unique or synergistic effects on the pulmonary vasculature, but the prevalence and risk factors for PH in HIV-HCV coinfectedpersons are not known. OBJECTIVES: To define the prevalence of echocardiographic PH in a cohort of patients with HIV-HCV coinfection, to compare this estimate with the reported prevalence of PH among those with HIV infection alone, and to identify potential risk factors for PH in coinfected individuals. METHODS: We performed a retrospective study of HIV-HCV coinfectedpatients followed at our institution from 2003 to 2012 with evidence of HCV infection (positive HCV antibody, measurable HCV ribonucleic acid viral load, and/or genotype) within 6 months of transthoracic echocardiogram. PH was defined by an estimated pulmonary artery systolic pressure (PASP) of greater than or equal to 40 mm Hg or more than moderate right ventricular dysfunction. We excluded those diagnosed with cirrhosis, left ventricular ejection fraction less than 50%, or more than moderate aortic or mitral valve disease. MEASUREMENTS AND MAIN RESULTS: Sixty-eight patients were included, and 43 had adequate estimates of PASP. The median (interquartile range) age was 52 (48-57) years, and 45 (67%) were men. Eight (19%) had PH, and three (7%) had more than moderate right ventricular dysfunction. After age and sex adjustment, interferon (IFN)-based HCV treatment was associated with higher PASP (β, 6.00 mm Hg; 95% confidence interval, 0.09-11.90; P = 0.047) and with the risk of PH (odds ratio, 5.65; 95% confidence interval, 1.07-29.93; P = 0.042). These associations persisted after adjustment for comorbidities but were attenuated by adjustment for duration of HCV diagnosis. CONCLUSIONS: The prevalence of echocardiographic PH may be higher in HIV-HCV coinfected individuals than in those with HIV monoinfection. IFN-based HCV treatment and time since HCV diagnosis were associated with the development of PH as assessed by echocardiography. Further studies are needed to examine HIV-HCV coinfection, HCV treatment, and duration of infection as possible causes of pulmonary vascular disease.
Entities:
Keywords:
echocardiography; hepatitis C; human immunodeficiency virus; interferon; pulmonary hypertension
Authors: Cleve O James; Ming-Bo Huang; Mafuz Khan; Minerva Garcia-Barrio; Michael D Powell; Vincent C Bond Journal: J Virol Date: 2004-03 Impact factor: 5.103
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelisa Journal: Eur J Echocardiogr Date: 2009-03
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Kristin E Mondy; John Gottdiener; E Turner Overton; Keith Henry; Tim Bush; Lois Conley; John Hammer; Charles C Carpenter; Erna Kojic; Pragna Patel; John T Brooks Journal: Clin Infect Dis Date: 2010-12-09 Impact factor: 9.079
Authors: Thomas Reiberger; Berit A Payer; Arnulf Ferlitsch; Wolfgang Sieghart; Florian Breitenecker; Maximilian C Aichelburg; Brigitte Schmied; Armin Rieger; Michael Trauner; Markus Peck-Radosavljevic Journal: Antivir Ther Date: 2012-09-05
Authors: Peter M George; Rekha Badiger; William Alazawi; Graham R Foster; Jane A Mitchell Journal: Pharmacol Ther Date: 2012-03-28 Impact factor: 12.310
Authors: Evan L Brittain; Meredith S Duncan; Joyce Chang; Olga V Patterson; Scott L DuVall; Cynthia A Brandt; Kaku A So-Armah; Matthew Goetz; Kathleen Akgun; Kristina Crothers; Courtney Zola; Joon Kim; Cynthia Gibert; Margaret Pisani; Alison Morris; Priscilla Hsue; Hilary A Tindle; Amy Justice; Matthew Freiberg Journal: Am J Respir Crit Care Med Date: 2018-04-01 Impact factor: 21.405
Authors: Courtney E Zola; Meredith S Duncan; Kaku So-Armah; Kristina A Crothers; Adeel A Butt; Cynthia L Gibert; Joon Woo W Kim; Joseph K Lim; Vincent Lo Re; Hilary A Tindle; Matthew S Freiberg; Evan L Brittain Journal: Sci Rep Date: 2020-10-30 Impact factor: 4.379
Authors: Meredith S Duncan; Charles W Alcorn; Matthew S Freiberg; Kaku So-Armah; Olga V Patterson; Scott L DuVall; Kristina A Crothers; Vincent Lo Re; Adeel A Butt; Joseph K Lim; Joon Woo Kim; Hilary A Tindle; Amy C Justice; Evan L Brittain Journal: Lancet Healthy Longev Date: 2021-06-16